Clinical Supplies Management Begins Global Expansion Through Acquisition of Theorem Clinical Research – Clinical Supplies in Frankfurt, Germany
GREENWICH, CT and MALVERN, PA (PRWEB) December 05, 2016 -- Clinical Supplies Management ("CSM"), a Great Point Partners ("GPP") portfolio company, today announced it has acquired the assets of Frankfurt, Germany based Theorem Clinical Research – Clinical Supplies ("TCS"). TCS was previously a subsidiary of Chiltern International and focuses on clinical trial drug packaging, labeling, storage, reconciliation, and distribution for pharmaceutical trials across Europe. With the acquisition of TCS, CSM has expanded to Western Europe and will be able to better serve the needs of its global clients.
“In pharmaceutical services, global capabilities matter – and we are building our business to ensure that we are providing the geographic scope of services our pharmaceutical clients demand,” said Scott Houlton, CSM CEO. “TCS has invested in a world-class facility that serves a diversified multi-national, European pharmaceutical client base. The business will continue to grow under CSM ownership and we look forward to working closely with them on global clinical trials.”
Rohan Saikia, Principal at Great Point Partners said, "The acquisition of TCS allows CSM to increase its global presence and add a world-class European team led by TCS’ Executive Director, Rüdiger Weber. This acquisition solidifies CSM’s position as a worldwide service provider in the clinical trials market."
Weber added, "CSM has delivered superb just-in time customer service and high quality solutions to the clinical trial packaging and labeling market for the last twenty years. Having access to their North American facilities will also allow us to service our current and future clients globally."
About Great Point Partners
Great Point Partners ("GPP"), founded in 2003 and based in Greenwich, CT, is a leading health care investment firm with approximately $1 billion of equity capital under management and 28 professionals, investing in the United States, Canada, and Western Europe. GPP is currently making new private equity investments from GPP II, which has closed on $215 million. Great Point manages capital in private (GPP I, $156 million and GPP II) and public (BioMedical Value Fund, approximately $525 million) equity funds. Great Point Partners has provided growth equity, growth recapitalization, and management buyout financing to more than 100 growing health care companies. The private equity funds invest across all sectors of the health care industry with particular emphasis on biopharmaceutical services and supplies, services, outsourcing, pharmaceutical infrastructure and information technology enabled businesses. The firm pursues a proactive and proprietary approach to sourcing investments and tuck-in acquisitions for its portfolio companies. Reach Great Point at 203-971-3300 or http://www.gppfunds.com.
About Clinical Supplies Management
Since 1997, CSM has been providing innovative solutions to meet the complex clinical supply challenges pharmaceutical and biotechnology companies face. CSM manages the clinical supply chain for hundreds of satisfied clients worldwide, providing services that keep clinical trials on time and on budget. CSM offers a full suite of cGMP-compliant services, continually delivering quality supplies to clinical sites and patients around the world. From Phase I all the way to large Phase III projects, CSM has the flexibility to meet the needs of all drug trials regardless of size and scope. CSM’s customer-centric approach, revolutionary processes and state-of-the-art clinical services increase efficiencies, reduce costs and improve outcomes for clinical trials. Some of CSM’s clinical services include packaging and labeling, storage and global distribution, controlled drug services, clinical supplies consulting, as well as returns, reconciliation and destruction. Reach CSM at 866-487-3276 or http://www.csmondemand.com
Edward Hjerpe, Great Point Partners, http://www.gppfunds.com, +1 203-971-3334, [email protected]
Share this article